Evidence map›Paper›PMID 38172930›Full record

ArticleBMC palliative care2024

Appropriate medication use in Dutch terminal care: study protocol of a multicentre stepped-wedge cluster randomized controlled trial (the AMUSE study).

M A M van Hylckama Vlieg, I E Pot, H P J Visser, M A C Jong, M J D L van der Vorst, B J van Mastrigt, J N A Kiers, P P P H van den Homberg, M F Thijs-Visser, E Oomen-de Hoop and 4 more

Registry-linked trialOpen access · goldAbstract readClinical Trial Protocol
PubMed Full text at PMC Publisher
In one paragraph

Article in BMC palliative care, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT05351281 (Appropriate Medication USE in Dutch Terminal Care), which is not on this map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
0.7field-weighted citation impact, top 35% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

NCT05351281 nacompletednot on this map

Appropriate Medication USE in Dutch Terminal Care: AMUSE Trial

TypeinterventionalSponsorProf.dr Carin (C.C.D.) van der RijtRan2022 to 2025Enrolled250ConditionsPalliative Care, Terminal Care, Medication Therapy Management, Clinical Decision Support System (CDSS)ArmsCDSS-OPTIMED
3 · Its place in the literature

Who cites it

1 citing paper in PubMed, 2 citations in OpenAlex.

  1. Observational
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

14 authors at 6 institutions in 1 country.

M A M van Hylckama VliegDepartment of Medical Oncology, Erasmus MC Cancer Institute, Rotterdam, The Netherlands. m.vanhylckamavlieg@erasmusmc.nl.
I E PotDepartment of Medical Oncology, Erasmus MC Cancer Institute, Rotterdam, The Netherlands.
H P J VisserDepartment of Internal Medicine, Noordwest Ziekenhuis, Alkmaar, The Netherlands.
M A C JongDepartment of Internal Medicine, Noordwest Ziekenhuis, Alkmaar, The Netherlands.
M J D L van der VorstDepartment of Internal Medicine, Center for Supportive and Palliative Care, Rijnstate Hospital, Arnhem, The Netherlands.
B J van MastrigtLaurens Cadenza Zuid, Rotterdam, The Netherlands.
J N A KiersFamily Medicine Network, Nijmegen, The Netherlands.
P P P H van den HombergGezondheidscentrum Krimpen, Krimpen aan den IJssel, The Netherlands.
M F Thijs-VisserDepartment of Medical Oncology, Ikazia Hospital, Rotterdam, The Netherlands.
E Oomen-de HoopDepartment of Medical Oncology, Erasmus MC Cancer Institute, Rotterdam, The Netherlands.
A van der HeideDepartment of Public Health, Erasmus MC, University Medical Center Rotterdam, Rotterdam, The Netherlands.
P H M van der KuyDepartment of Hospital Pharmacy, Erasmus MC, University Medical Center Rotterdam, Rotterdam, The Netherlands.
C C D van der RijtDepartment of Medical Oncology, Erasmus MC Cancer Institute, Rotterdam, The Netherlands.
E C T GeijtemanDepartment of Medical Oncology, Erasmus MC Cancer Institute, Rotterdam, The Netherlands.
Erasmus MC Cancer Institute · NLErasmus MC · NLNoordwest Ziekenhuisgroep · NLIkazia Ziekenhuis · NLLaurens · NLRijnstate Hospital · NL

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundPolypharmacy is common among patients with a limited life expectancy, even shortly before death. This is partly inevitable, because these patients often have multiple symptoms which need to be alleviated. However, the use of potentially inappropriate medications (PIMs) in these patients is also common. Although patients and relatives are often willing to deprescribe medication, physicians are sometimes reluctant due to the lack of evidence on appropriate medication management for patients in the last phase of life. The aim of the AMUSE study is to investigate whether the use of CDSS-OPTIMED, a software program that gives weekly personalized medication recommendations to attending physicians of patients with a limited life expectancy, improves patients' quality of life.

methodsA multicentre stepped-wedge cluster randomized controlled trial will be conducted among patients with a life expectancy of three months or less. The stepped-wedge cluster design, where the clusters are the different study sites, involves sequential crossover of clusters from control to intervention until all clusters are exposed. In total, seven sites (4 hospitals, 2 general practices and 1 hospice from the Netherlands) will participate in this study. During the control period, patients will receive 'care as usual'. During the intervention period, CDSS-OPTIMED will be activated. CDSS-OPTIMED is a validated software program that analyses the use of medication based on a specific set of clinical rules for patients with a limited life expectancy. The software program will provide the attending physicians with weekly personalized medication recommendations. The primary outcome of this study is patients' quality of life two weeks after baseline assessment as measured by the EORTC QLQ-C15-PAL questionnaire, quality of life question. DISCUSSION: This will be the first study investigating the effect of weekly personalized medication recommendations to attending physicians on the quality of life of patients with a limited life expectancy. We hypothesize that the CDSS-OPTIMED intervention could lead to improved quality of life in patients with a life expectancy of three months or less.

trial registrationThis trial is registered at ClinicalTrials.gov (NCT05351281, Registration Date: April 11, 2022).

Indexed as

General PracticeTerminal CareHospitalsHumansMulticenter Studies as TopicQuality of LifeRandomized Controlled Trials as TopicSurveys and QuestionnairesClinical decision support systemsDeprescribingDrug therapyPalliative carePotentially inappropriate medications (PIMs)Quality of lifeStepped-wedge cluster randomized controlled trial

Identifiers

PMID38172930
PMCPMC10762916
OpenAlexW4390545874

What Socratic holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.